APA (7th ed.) Citation

G, H., K, P., W, W., HJ, S., J, B., M, S., . . . B, P. (1999). Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clinical chemistry and laboratory medicine, 37(1), 47. https://doi.org/10.1515/CCLM.1999.007

Chicago Style (17th ed.) Citation

G, Hoffmann, Pollow K, Weikel W, Strittmatter HJ, Bach J, Schaffrath M, Knapstein P, Melchert F, and Pollow B. "Urokinase and Plasminogen Activator-inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as a Function of Histopathological Parameters." Clinical Chemistry and Laboratory Medicine 37, no. 1 (1999): 47. https://doi.org/10.1515/CCLM.1999.007.

MLA (9th ed.) Citation

G, Hoffmann, et al. "Urokinase and Plasminogen Activator-inhibitor (PAI-1) Status in Primary Ovarian Carcinomas and Ovarian Metastases Compared to Benign Ovarian Tumors as a Function of Histopathological Parameters." Clinical Chemistry and Laboratory Medicine, vol. 37, no. 1, 1999, p. 47, https://doi.org/10.1515/CCLM.1999.007.